医脉通编辑整理，未经授权请勿转载

2022年第19届国际骨髓瘤学会（IMS）年会将于2022年8月25-27日在美国洛杉矶举行，会议由IMS主办，致力于促进多发性骨髓瘤和相关浆细胞疾病的最新突破性科学和临床交流。会议内容涵盖最新的基因学研究进展、对免疫与微环境失调的见解、新的药物靶点和新药进展等。随着我国医疗水平的提高和科学技术的发展，越来越多的中国专家在国际会议上展现风采。今年，中国专家有33篇Poster入围IMS年会，让我们一起来盘点下吧！

1.摘要号：P-014

标题：High function, but low level stem cell memory T cells in multiple myeloma: a potential tumor targeted and long lived cell therapy population.

通讯作者：付蓉

单位：天津医科大学总医院

2.摘要号：P-027

标题：Lenalidomide does not affect platelet function in vitro.

通讯作者：刘澎

单位：复旦大学附属中山医院

3.摘要号：P-029

标题：The association of microbiota composition and proteasome inhibitor-related gastrointestinal adverse effects.

通讯作者：庄俊玲

单位：北京协和医院

4.摘要号：P-035

标题：Ixazomib versus lenalidomide or ixazomib and lenalidomide combination as maintenance regimen for patients with multiple myeloma: interim analysis of a multi-center prospective study in China.

通讯作者：庄俊玲

单位：北京协和医院

5.摘要号：P-037

标题：Chinese herbal medicine ‘Diwu’ suppresses myeloma bone disease via ERK/MAPK signaling pathway by targeting CCL3.

通讯作者：庄俊玲

单位：北京协和医院

6.摘要号：P-044

标题：Genetically undetectable and negative minimal residual disease after induction therapy are equally important for survival in multiple myeloma.

通讯作者：安刚

单位：中国医学科学院血液病医院

7.摘要号：P-045

标题：Minimal residual disease detected by a novel isotope labeled PET/CT combined with next-generation flowcytometry in newly diagnosed multiple myeloma.

通讯作者：庄俊玲

单位：北京协和医院

8.摘要号：P-048

标题：The value of autologous hematopoietic stem cell transplantation in multiple myeloma patients with MRD negative after early induction therapy.

通讯作者：安刚

单位：中国医学科学院血液病医院

9.摘要号：P-049

标题：Detection of multiple myeloma cell load by multiple-color flow cytometry as a useful approach for analyzing immune cell subsets in patients.

通讯作者：付蓉

单位：天津医科大学总医院

10.摘要号：P-050

标题：Detecting of myeloma cell-derived MPs by flow cytometry as a potential strategy to reflect minimal residual disease in MM patients.

通讯作者：付蓉

单位：天津医科大学总医院

11.摘要号：P-054

标题：Neoplastic plasma cells in stem cell collection have no effect on the survival of multiple myeloma patients receiving autologous stem cell transplantation.

通讯作者：安刚

单位：中国医学科学院血液病医院

12.摘要号：P-059

标题：Chemotherapy-induced transcriptional reprogramming of multiple myeloma revealed by single-cell RNA sequencing.

通讯作者：侯健

单位：上海交通大学医学院附属仁济医院

13.摘要号：P-061

标题：Differential expression profile and bioinformatic analysis of serum exosomal miRNA in multiple myeloma patients.

通讯作者：邱录贵

单位：中国医学科学院血液病医院

14.摘要号：P-063

标题：The independent adverse prognostic significance of 1q21 gain in newly diagnosed multiple myeloma patients.

通讯作者：吴德沛

单位：苏州大学附属第一医院

15.摘要号：P-087

标题：Single-cell RNA sequencing reveals ZNF683 as a key regulator of NK cell exhaustion in multiple myeloma.

通讯作者：侯健

单位：上海交通大学医学院附属仁济医院

16.摘要号：P-088

标题：Bone marrow mesenchymal stem cells regulate the function of NK cells via TIM-3/Gal-9 in multiple myeloma.

通讯作者：付蓉

单位：天津医科大学总医院

17.摘要号：P-089

标题：Disordered metabolism mediates the immunosuppressive microenvironment in multiple myeloma.

通讯作者：郝牧

单位：中国医学科学院血液病医院

18.摘要号：P-094

标题：The expression and prognostic significance of piRNA-823 in multiple myeloma.

通讯作者：周帆

单位：上海市静安区闸北中心医院

19.摘要号：P-095

标题：Exosomal miR-27b-3p suppresses CD28 expression in T cells and facilitates immune escape of multiple myeloma.

通讯作者：郝牧

单位：中国医学科学院血液病医院

20.摘要号：P-096

标题：MiR-27b-3p suppresses CD28 expression in T cells and facilitates immune escape of multiple myeloma.

通讯作者：郝牧

单位：中国医学科学院血液病医院

21.摘要号：P-118

标题：Three distinct destines of malignant plasma cells based on single-cell transcriptomes and evolutionary trajectories.

通讯作者：刘澎

单位：复旦大学附属中山医院

22.摘要号：P-120

标题：Indirubin-3’-monoxime acts as proteasome inhibitor: therapeutic application in multiple myeloma.

通讯作者：郝牧

单位：中国医学科学院血液病医院

23.摘要号：P-127

标题：Evaluation of the Mayo Additive Staging System in patients with newly diagnosed multiple myeloma, a real-world analysis.

通讯作者：周帆

单位：上海市静安区闸北中心医院

24.摘要号：P-139

标题：Pim-2 kinase regulate the expression of TIGIT and function of NK cells from multiple myeloma patients.

通讯作者：付蓉

单位：天津医科大学总医院

25.摘要号：P-165

标题：The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria.

通讯作者：安刚

单位：中国医学科学院血液病医院

26.摘要号：P-225

标题：The optimal dose of thalidomide on the treatment of newly diagnosed multiple myeloma: real-world experience in Taiwan.

通讯作者：Chieh-Lin Jerry Teng

单位：台中荣民总医院

27.摘要号：P-226

标题：Bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients: a real-world study of China.

通讯作者：安刚

单位：中国医学科学院血液病医院

28.摘要号：P-227

标题：The prognostic role of 1q21 gain/amp in newly diagnosed multiple myeloma: the faster, the worse.

通讯作者：Panpan Li

单位：复旦大学附属中山医院

29.摘要号：P-256

标题：Proteasome inhibition prolonged by in-class transitioned ixazomib-based regimen in newly diagnosed and first-line relapsed multiple myeloma patients in China: a real-world study.

通讯作者：陈文明

单位：首都医科大学附属北京朝阳医院

30.摘要号：P-266

标题：Favorable outcomes of 3-weekly daratumumab-based regimens in relapsed/refractory multiple myeloma: impact of MRD, rapid doubling time, LDH, triplets and quadruplets.

通讯作者：Chor Sang Chim

单位：香港大学玛丽医院

31.摘要号：P-274

标题：Treatment patterns among patients with relapsed/refractory multiple myeloma (RRMM) in Taiwan.

通讯作者： Chieh-Lin Jerry Teng

单位：台中荣民总医院

32.摘要号：P-285

标题：Single-cell RNA-seq reveals XBP1-SLC38A2 axis as a player in immunosuppressive T lymphocytes in multiple myeloma.

通讯作者：侯健

单位：上海交通大学医学院附属仁济医院

33.摘要号：P-286

标题：Identification of myeloma-initiating cells and novel therapeutic target by single-cell sequencing.

通讯作者：郝牧

单位：中国医学科学院血液病医院

排名不分先后，按摘要号进行。如有遗漏，请给我们留言。